



Brenda H. Jarrell, PhD

CHAIR, LIFE SCIENCES

📞 617-248-5175 ✉️ bjarrell@choate.com

Dr. Brenda Herschbach Jarrell, Chair of Choate's Life Sciences Group, is described by clients as an IP lawyer with keen business savvy. Her extensive technical credentials make her well-versed in a wide variety of technologies in the biotech, pharmaceutical, and specialty chemical industries. She represents companies and institutions at all stages of the life sciences business lifecycle, as well as those who invest in them, guiding IP protection and competitive positioning strategies, negotiating strategic transactions, and providing creative solutions to IP and technology-related challenges. Throughout her career, Brenda has advised multiple clients from Series A through their eventual IPOs.

As one of the foremost respected IP strategists in the country, Brenda is routinely awarded the recognition of "Attorney of the Year" by several respected rankings providers across a variety of categories.

Some of her clients include Adimab, Aleta Biotherapeutics, Angion Biomedica Corp., Apellis Pharmaceuticals, Atlas Venture, Base Genomic, Biogen, BioNTech, Casma Therapeutics, Celsius Therapeutics, Eirion Therapeutics, FogPharma, FORMA Therapeutics, Gilead, Ginkgo BioWorks, Kernal Biologics, LogicBio Therapeutics, Mereo BioPharma, Olema Pharmaceuticals, Progenics Pharmaceuticals, Regeneron Pharmaceuticals, ReNetX Bio, Scipher Medicine Corporation, Surge Therapeutics, Syros Pharmaceuticals, Third Rock Ventures, WAVE Life Sciences, and Venrock.

Brenda is a member of Choate's Executive Committee.

Focus Areas

Intellectual Property
Private Equity and M&A
Life Sciences and
Technology

Admissions

- Massachusetts
- U.S. Patent & Trademark Office

Representative Engagements

Patent Prosecution and Counseling

- Has represented **nucleic acid therapeutics company** from start-up through IPO and into clinical trials, crafting an IP portfolio with layered protection of both platform technologies and key product candidates, including in support of major collaborations.
- Works with a **start-up company** to navigate a complex small molecule patent landscape and develop an exclusivity proposition attractive to large pharmaceutical partners.
- Extensive experience representing clients in the **metabolic engineering space**, producing products

ranging from specialty chemicals to pharmaceuticals to oils, including fuels.

- Develops **life-cycle management strategies** for various clients, large and small, to protect assets whose base composition of matter protection may be expiring before products can be commercialized.
- Represents various **clients developing biologic therapeutics** (both antibody-based and cellular), with particular focus on counseling with respect to freedom to operate while also securing strong protection, worldwide, for assets, including those whose major uses are likely to be in combination and/or in specialized patient populations.
- Helps coordinate **worldwide protection and dispute strategy** on behalf of client with ongoing matters, both offensive and defensive, in multiple jurisdictions.
- Assists **venture capital groups** in assessing intellectual property landscape relating to a novel strategy for tackling complex disorders, including negotiating option and license agreements, and partnerships with research laboratories around the world.

Patent Trial and Appeal Board Proceedings

- **Progenics Pharmaceuticals, Inc. v. Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V., PTAB:** Counsel for Progenics Pharmaceuticals, Inc. in a PGR proceeding challenging a patent directed to compounds for preparing 18F-radiolabeled Prostate-Specific Membrane Antigen (PSMA)-targeting conjugates.
- **Regeneron Pharmaceuticals, Inc. v. Kymab Ltd., PTAB:** Counsel for Regeneron Pharmaceuticals in multiple IPR proceedings challenging patents directed to transgenic mice and methods of using transgenic mice.
- **Guardant Health, Inc. v. Foundation Medicine, Inc., PTAB:** Counsel for Foundation Medicine in IPR proceedings defending patents protecting innovative comprehensive genomic cancer assays using next generation sequencing.
- **Hybrigenics SA v. FORMA Therapeutics, Inc., PTAB:** Counsel for FORMA Therapeutics, Inc. in a PGR proceeding defending a patent protecting novel inhibitors of ubiquitin-specific protease 7 (USP7).

Professional & Community Involvement

- Board of Advisors of the American Repertory Theater
- Former Area I Coordinator for the North American Junior and Young Rider Championships, United States Eventing Association